Pralatrexate
- Generic Name
- Pralatrexate
- Brand Names
- Folotyn
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N7O5
- CAS Number
- 146464-95-1
- Unique Ingredient Identifier
- A8Q8I19Q20
- Background
Pralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma . Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts. Compared to methotrexate, pralatrexate has better accumulation in cancer cells. Pralatrexate is designed to have a hi...
- Indication
Pralatrexate is indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma.
- Associated Conditions
- Cutaneous T-Cell Lymphoma (CTCL), Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
- Associated Therapies
- -
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06561048
- Locations
- 🇺🇸
Corvus Clinical Trials Information, Burlingame, California, United States
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
- Conditions
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 50
- Registration Number
- NCT04747236
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
- Conditions
- Anaplastic Large Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypeRecurrent Anaplastic Large Cell LymphomaRecurrent Angioimmunoblastic T-Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular LymphomaRecurrent Hepatosplenic T-Cell LymphomaRecurrent Mature T- Cell and NK-Cell Non-Hodgkin LymphomaRecurrent Monomorphic Epitheliotropic Intestinal T-cell LymphomaRecurrent Mycosis Fungoides
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT03598998
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma
- Conditions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT03356678
- Locations
- 🇰🇷
81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
- Conditions
- Interventions
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Jennifer Amengual
- Registration Number
- NCT03355768
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
- Conditions
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
- Target Recruit Count
- 85
- Registration Number
- NCT03349333
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 37
- Registration Number
- NCT03240211
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸Allegheny Health Network, Pittsburgh, Pennsylvania, United States
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 148
- Registration Number
- NCT03161223
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Taiwan Mundipharma Pharmaceuticals Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT03150602
- Locations
- 🇨🇳
Ntional Taiwan University Hospital, Taipei, Taiwan
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Jennifer Amengual
- Target Recruit Count
- 57
- Registration Number
- NCT01947140
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.